about
Persistent high mortality in advanced HIV/TB despite appropriate antiretroviral and antitubercular therapy: an emerging challengeMatrix Metalloproteinases in Tuberculosis-Immune Reconstitution Inflammatory Syndrome and Impaired Lung Function Among Advanced HIV/TB Co-infected Patients Initiating Antiretroviral TherapyTuberculin skin test result and risk of death among persons with active TBMultiple oncogenic viruses identified in Ocular surface squamous neoplasia in HIV-1 patients.Overestimates of survival after HAART: implications for global scale-up effortsLost but not forgotten--the economics of improving patient retention in AIDS treatment programs.A simple novel method for determining mortality rates in HIV treatment programs worldwide.Early mortality and AIDS progression despite high initial antiretroviral therapy adherence and virologic suppression in BotswanaEarly mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysisIsoniazid resistance and death in patients with tuberculous meningitis: retrospective cohort studyExtended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species: risk factors for colonization and impact of antimicrobial formulary interventions on colonization prevalence.Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections.Association between tuberculin skin test result and clinical presentation of tuberculosis diseaseIsoniazid-resistant tuberculous meningitis, United States, 1993-2005.Early antiretroviral therapy is protective against epilepsy in children with human immunodeficiency virus infection in botswanaAMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial.Urine colorimetry to detect Low rifampin exposure during tuberculosis therapy: a proof-of-concept studyImmunological profiling of tuberculosis-associated immune reconstitution inflammatory syndrome and non-immune reconstitution inflammatory syndrome death in HIV-infected adults with pulmonary tuberculosis starting antiretroviral therapy: a prospectivVitamin D status in HIV-infected patients with and without tuberculosis: a pilot study.Upregulation of the phthiocerol dimycocerosate biosynthetic pathway by rifampin-resistant, rpoB mutant Mycobacterium tuberculosisRobust Reconstitution of Tuberculosis-Specific Polyfunctional CD4+ T-Cell Responses and Rising Systemic Interleukin 6 in Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory SyndromeFirst Use of Multiple Imputation with the National Tuberculosis Surveillance System.The use of HAART is associated with decreased risk of death during initial treatment of cryptococcal meningitis in adults in Botswana.Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trialHIV infection and glycemic response to newly initiated diabetic medical therapy.Early immunologic failure is associated with early mortality among advanced HIV-infected adults initiating antiretroviral therapy with active tuberculosisAntiretroviral failure despite high levels of adherence: discordant adherence-response relationship in Botswana.Slow efavirenz metabolism genotype is common in Botswana.Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adults.Brief Report: CYP2B6 516G>T Minor Allele Protective of Late Virologic Failure in Efavirenz-Treated HIV-Infected Patients in Botswana.Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation.CYP2B6 genotypes and early efavirenz-based HIV treatment outcomes in Botswana.Markers of gut dysfunction do not explain low rifampicin bioavailability in HIV-associated TB.Elevated Pre-Antiretroviral Therapy CD39+CD8+ T Cell Frequency Is Associated With Early Mortality in Advanced Human Immunodeficiency Virus/Tuberculosis Co-infection.Comparative Effectiveness of Diabetic Oral Medications Among HIV-Infected and HIV-Uninfected Veterans.Effects of sex and alcohol use on antiretroviral therapy outcomes in Botswana: a cohort study.Ocular surface squamous neoplasia among HIV-infected patients in Botswana.Early versus delayed antiretroviral therapy and cerebrospinal fluid fungal clearance in adults with HIV and cryptococcal meningitis.In-hospital mortality of HIV-infected cryptococcal meningitis patients with C. gattii and C. neoformans infection in Gaborone, Botswana.Cryptococcus and lymphocytic meningitis in Botswana.
P50
Q28088557-8D216689-8DE1-4A9B-ACE2-059BD48A551AQ28389802-A4B25003-2117-499D-B55C-89CCBBCAD331Q28535009-C4267E64-1D86-4048-97A1-4052DDA5A1B8Q30387346-2AB93F90-D94B-40DE-BE55-893CA2267DA2Q33322531-266960EF-6E26-4089-B538-19D3085598BDQ33512904-DB87501A-44FE-449F-B700-BE2547E4CF46Q33803726-5893B4DE-882B-4E26-A6C9-F9CEA62EBC57Q33941267-DC50CF38-0A26-4FF5-BFB1-37BABDAD24CEQ34119037-170A7E5B-EC35-46FA-A042-71DF43ADB4C7Q34125176-2635228B-87F9-46A7-8306-B072DBC846D8Q34652460-EE279874-EED8-4030-951F-241743DE08F7Q34737913-91EF561B-C01D-4D80-8F51-B23339AA8C0BQ35008119-1162441B-E4D7-4FD0-952B-22FDEED89345Q35193575-2C1B323B-9BEC-4D3C-8563-74A35B4C91FCQ35655977-E4E856D0-6FA1-4E4C-A23A-B34C392EBDC8Q35776693-F595337B-9D22-4228-A9CB-CAFDAA132A39Q36036963-6A82FD82-BE27-4202-B4AE-7356A7DE1B45Q36219464-3D508FE0-C89D-4D0C-BC5F-A2C541C6886AQ36293387-0BD66136-1C8D-44E7-B113-C2E3DC94FE70Q36397155-197CDD6A-2214-4BAF-986A-8335B19CD21CQ36635710-5260617D-8900-4B2A-815D-119F40745296Q36819897-FF916B72-F5C5-45DF-AE9E-62D9251CACDDQ36991683-00596497-14F1-4848-836A-BBF37D4A548CQ37061089-EEF88E6D-4450-4A3F-BDD8-F51FAFAA8348Q37178529-8F04F793-395A-4E2C-B66E-D55C7DE36652Q37272336-4CE2D68A-A812-4998-8B87-836C5A570F9EQ37340992-F0EFB300-83E2-4EE2-90E1-AF26CC52DD99Q37350627-2FEB9533-443E-4D53-A130-13FDA77889E5Q38662366-EE5AE7F6-0117-46DC-BFB6-10DDD8636817Q38686531-3E5213C8-2A3D-4D09-BE6A-81939AB7DE1CQ38803026-A522105A-E50E-4A77-8FE8-767150CEE26AQ40129359-9FDE510C-1913-495C-A25A-9EF1DB2D6A97Q40226194-AE4826BF-A7AA-4F8D-A2DE-772D7A9BC92EQ40330870-8C8BE30A-20F1-4B4E-84C6-F458BD539876Q40538325-ADD77FE3-C261-4A64-9A7F-56507B053AFFQ40603410-EF89126A-960B-4A4E-A4C9-A4BA4CF53C5DQ40793981-528FAE0C-290F-4F1E-B524-CECC01F2CBE5Q40796320-9E8E9229-4501-4271-8609-DE6D1B9B0204Q40797823-27E84FA1-E42B-4402-827B-D315D2AD29A5Q40798536-51EBFC4C-9667-4986-BD4C-7BECC7C500EC
P50
name
Gregory P Bisson
@en
Gregory P Bisson
@nl
type
label
Gregory P Bisson
@en
Gregory P Bisson
@nl
prefLabel
Gregory P Bisson
@en
Gregory P Bisson
@nl